Company Announcement
- Submission
based on positive pivotal innovaTV 204 trial results presented at
the European Society of Medical Oncology Virtual Congress
2020
COPENHAGEN, Denmark and
BOTHELL, Wash.; Feb 10, 2021 –
Genmab A/S (Nasdaq: GMAB) and Seagen
Inc. (Nasdaq: SGEN) today
announced the submission of a Biologics License Application (BLA)
to the U.S. Food and Drug Administration (FDA)
seeking accelerated approval for tisotumab
vedotin. This BLA requests FDA approval of tisotumab
vedotin for the treatment of patients with recurrent or metastatic
cervical cancer with disease progression on or after chemotherapy.
The submission is based on the results of the innovaTV 204 pivotal
phase 2 single-arm clinical trial evaluating tisotumab vedotin as
monotherapy in this setting. The topline results from the phase 2
study were announced in June 2020 and data were presented at the
European Society for Medical Oncology (ESMO) Virtual Congress 2020.
Tisotumab vedotin is an investigational antibody-drug conjugate
(ADC) directed to tissue factor (TF), a cell-surface protein
expressed on multiple solid tumors including cervical cancer and is
associated with tumor growth, angiogenesis, metastasis and poor
prognosis.1
“This BLA submission is an important step toward our goal of
improving the lives of women with recurrent or metastatic cervical
cancer. I would like to thank the patients, nurses, physicians and
researchers who participated in the innovaTV 204 trial, which is
the basis of this submission,” said Jan van de Winkel, Ph.D., Chief
Executive Officer of Genmab. “We believe, if approved, tisotumab
vedotin as monotherapy has the potential to become an important
treatment option for women with recurrent or metastatic cervical
cancer, who have disease progression on or after chemotherapy.”
“In the pivotal phase 2 study, tisotumab vedotin induced
clinically meaningful and durable responses in this difficult to
treat cervical cancer patient population, with a manageable and
tolerable safety profile. Today’s submission marks an important
milestone for tisotumab vedotin and a potential advance for
patients with recurrent or metastatic cervical cancer for whom
there is a high unmet need for effective new therapies,” said Roger
Dansey, M.D., Chief Medical Officer at Seagen. “We look forward to
working with the FDA on the review of the application.”
About Cervical CancerCervical cancer originates
in the cells lining the cervix. Over 13,500 women are expected to
be diagnosed with invasive cervical cancer in the U.S. in 2020,
with approximately 4,200 deaths.2 Cervical cancer remains one of
the leading causes of cancer death in women globally, with over
311,000 women dying annually; the vast majority of these women
being in the developing world.3 Routine medical examinations and
human papillomavirus (HPV) vaccines have lowered the incidence of
cervical cancer in the developed world. Despite these advances,
women are still diagnosed with cervical cancer, which often recurs
or becomes metastatic. Current therapies for previously treated
recurrent or metastatic cervical cancer generally result in limited
objective response rates of typically less than 15 percent with
median overall survival ranging from 6.0 to 9.4 months. 4-10
About the innovaTV 204 TrialThe innovaTV 204
trial (also known as GCT1015-04 or innovaTV 204/GOG-3023/ENGOT-cx6)
is an ongoing single-arm, global, multicenter study of tisotumab
vedotin for patients with recurrent or metastatic cervical cancer
who were previously treated with doublet chemotherapy with or
without bevacizumab. Additionally, patients were eligible if they
had received up to two prior lines of therapy in the recurrent or
metastatic setting. In the study, 101 patients were treated with
tisotumab vedotin at multiple centers in the U.S. and Europe. The
primary endpoint of the trial was confirmed objective response rate
per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as
assessed by independent central review. Key secondary endpoints
included duration of response, progression-free survival, overall
survival, safety and tolerability.
The study was conducted by Genmab in collaboration with Seagen,
European Network of Gynaecological Oncological Trial Groups (ENGOT)
and the Gynecologic Oncology Group (GOG) Foundation. For more
information about the phase 2 innovaTV 204 clinical trial and
other clinical trials with tisotumab vedotin, please visit
www.clinicaltrials.gov.
About Tisotumab VedotinTisotumab vedotin is an
investigational antibody-drug conjugate (ADC) composed of Genmab’s
fully human monoclonal antibody specific for tissue factor and
Seagen’s ADC technology that utilizes a protease-cleavable linker
that covalently attaches the microtubule-disrupting agent
monomethyl auristatin E (MMAE) to the antibody and releases it upon
internalization, inducing target cell death. In cancer biology,
tissue factor is a cell-surface protein and associated with tumor
growth, angiogenesis, metastasis and poor prognosis.1 Based on its
elevated expression in multiple solid tumors and its rapid
internalization, tissue factor was selected as a target for an ADC
approach. Tisotumab vedotin is being co-developed by Genmab and
Seagen, under an agreement in which the companies share all costs
and profits for the product on a 50:50 basis.
Tisotumab vedotin is being evaluated in a global phase 3,
randomized clinical trial called innovaTV 301 versus investigator’s
choice of chemotherapy in recurrent or metastatic cervical cancer.
The primary endpoint is overall survival and secondary endpoints
include progression-free survival, duration of response, objective
response rate, safety and tolerability. Enrollment is ongoing and
the study is intended to support global registrations. In addition,
tisotumab vedotin is being evaluated in ongoing clinical trials as
monotherapy in recurrent or metastatic cervical cancer, ovarian
cancer, and other solid tumors and in combination with commonly
used therapies in recurrent or metastatic cervical cancer. These
trials are evaluating tisotumab vedotin on a weekly or every
three-week dosing schedule. More information about the innovaTV 301
clinical trial, including enrolling sites, as well as other ongoing
clinical trials is available at www.clinicaltrials.gov.
About Genmab Genmab is an international
biotechnology company with a core purpose to improve the lives of
patients with cancer. Founded in 1999, Genmab is the creator of
multiple approved antibody therapeutics that are marketed by its
partners. The company aims to create, develop and commercialize
differentiated therapies by leveraging next-generation antibody
technologies, expertise in antibody biology, translational research
and data sciences and strategic partnerships. To create novel
therapies, Genmab utilizes its next-generation antibody
technologies, which are the result of its collaborative company
culture and a deep passion for innovation. Genmab’s proprietary
pipeline consists of modified antibody candidates, including
bispecific T-cell engagers and next-generation immune checkpoint
modulators, effector function enhanced antibodies and antibody-drug
conjugates. The company is headquartered in Copenhagen, Denmark
with locations in Utrecht, the Netherlands, Princeton, New Jersey,
U.S. and Tokyo, Japan. For more information, please visit
Genmab.com. About SeagenSeagen Inc. is a global
biotechnology company that discovers, develops and commercializes
transformative cancer medicines to make a meaningful difference in
people’s lives. ADCETRIS® (brentuximab vedotin) and PADCEV®
(enfortumab vedotin-ejfv) use the Company’s industry-leading
antibody-drug conjugate (ADC) technology. ADCETRIS is approved in
certain CD30-expressing lymphomas, and PADCEV is approved in
certain metastatic urothelial cancers. TUKYSA® (tucatinib), a small
molecule tyrosine kinase inhibitor, is approved in certain
HER2-positive metastatic breast cancers. The company is
headquartered in the Seattle, Washington area, with locations in
California, Switzerland and the European Union For more information
on our robust pipeline, visit www.seagen.com and follow
@SeagenGlobal on Twitter.
Genmab
Contacts: For Media
Relations:Marisol Peron, Senior Vice President, Global
Investor Relations & CommunicationsT: +1 609 524 0065; E:
mmp@genmab.com
For Investor Relations: Andrew Carlsen, Senior
Director, Head of Investor RelationsT: +45 3377 9558; E:
acn@genmab.com
Seagen Contact:For Media and
Investors:Peggy Pinkston(425)
527-4160ppinkston@seagen.com
Genmab Forward Looking StatementsThis Company
Announcement contains forward looking statements. The words
“believe”, “expect”, “anticipate”, “intend” and “plan” and similar
expressions identify forward looking statements. Actual results or
performance may differ materially from any future results or
performance expressed or implied by such statements. The important
factors that could cause our actual results or performance to
differ materially include, among others, risks associated with
pre-clinical and clinical development of products, uncertainties
related to the outcome and conduct of clinical trials including
unforeseen safety issues, uncertainties related to product
manufacturing, the lack of market acceptance of our products, our
inability to manage growth, the competitive environment in relation
to our business area and markets, our inability to attract and
retain suitably qualified personnel, the unenforceability or lack
of protection of our patents and proprietary rights, our
relationships with affiliated entities, changes and developments in
technology which may render our products or technologies obsolete,
and other factors. For a further discussion of these risks, please
refer to the risk management sections in Genmab’s most recent
financial reports, which are available on www.genmab.com and the
risk factors included in Genmab’s most recent Annual Report on Form
20-F and other filings with the U.S. Securities and Exchange
Commission (SEC), which are available at www.sec.gov. Genmab does
not undertake any obligation to update or revise forward looking
statements in this Company Announcement nor to confirm such
statements to reflect subsequent events or circumstances after the
date made or in relation to actual results, unless required by law.
Genmab A/S and/or its subsidiaries own the following trademarks:
Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the
Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination
with the DuoBody logo®; HexaBody®; HexaBody in combination with the
HexaBody logo®; DuoHexaBody®; HexElect®; and UniBody®. Arzerra® and
Kesimpta® are trademarks of Novartis AG or its affiliates.
DARZALEX® and DARZALEX FASPRO® are trademarks of Janssen
Pharmaceutica NV. TEPEZZA® is a trademark of Horizon Therapeutics
plc.
Seagen Forward Looking Statements Certain of
the statements made in this press release are forward looking, such
as those, among others, relating to the potential FDA approval of
tisotumab vedotin for the treatment of patients with recurrent or
metastatic cervical cancer with disease progression on or after
chemotherapy based on the results of the innovaTV 204 trial,
clinical trials of tisotumab vedotin and its therapeutic potential.
Actual results or developments may differ materially from those
projected or implied in these forward-looking statements. Factors
that may cause such a difference include the possibility that the
Biologics License Application submission based on the innovaTV 204
trial may not be accepted for filing by, or ultimately approved by,
the FDA in a timely manner or at all or with the requested label;
that subsequent clinical trials may fail to establish sufficient
efficacy; that adverse events or safety signals may occur; and that
adverse regulatory actions may occur as tisotumab vedotin advances
in clinical trials even after promising results in earlier clinical
trials. More information about the risks and uncertainties faced by
Seagen is contained under the caption “Risk Factors” included in
the Company’s Quarterly Report on Form 10-Q for the quarter ended
September 30, 2020 and the Company’s Current Report on Form 8-K
dated December 30, 2020 filed with the Securities and Exchange
Commission. Seagen disclaims any intention or obligation to update
or revise any forward-looking statements, whether as a result of
new information, future events or otherwise, except as required by
law.
References:1 Rondon et al. Semin Thromb Hemost
2019; 45:396–412.2 National Cancer Institute SEER. “Cancer Stat
Facts: Cervix Uteri Cancer.” Available at
https://seer.cancer.gov/statfacts/html/cervix.html. Last accessed
April 2020.3 Global Cancer Statistics 2018: GLOBOCAN Estimates of
Incidence and Mortality Worldwide for 36 Cancers in 185 countries
https://www.iarc.fr/news-events/global-cancer-statistics-2018-globocan-estimates-of-incidence-and-mortality-worldwide-for-36-cancers-in-185-countries/.4
Miller et al., Gynecol Oncol 2008; 110:65. 5 Bookman et al.,
Gynecol Oncol 2000; 77:446. 6 Garcia et al., Am J Clin Oncol 2007;
30:428. 7 Monk et al., J Clin Oncol 2009; 27:1069. 8 Santin et al.,
Gynecol Oncol 2011; 122:495. 9 Schilder et al., Gynecol Oncol 2005;
96:10310 Chung HC et al. J Clin Oncol 2019; 37:1470.
no. 08CVR no. 2102 3884LEI Code 529900MTJPDPE4MHJ122
Genmab A/SKalvebod Brygge 431560 Copenhagen VDenmark
- 021021_CA08_ innovaTV 204 BLA submission
Genesis Healthcare (NYSE:GEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Genesis Healthcare (NYSE:GEN)
Historical Stock Chart
From Sep 2023 to Sep 2024